Table 1_Subsequent treatment strategies following rituximab-resistance in AQP4-IgG+ neurom

Meiqun Deng's case series describes alternative treatments for 10 adults with AQP4-IgG+ neuromyelitis optica spectrum disorder who exhibited disease activity despite sustained B cell depletion post-rituximab. The dataset, last updated in April 2026, details patient outcomes after switching to therapies like inebilizumab, satralizumab, eculizumab, or de-escalation strategies over a median follow-up of 28.4 months.

Use Cases

• Compare relapse rates across different subsequent treatment strategies based on the described patient outcomes.
• Analyze the safety profile of monoclonal antibodies versus de-escalation therapies based on the reported adverse events.
• Generate hypotheses for clinical trial design in rituximab-resistant NMOSD based on the real-world observational data.

Strengths

• Includes data on 10 specific patients with a defined condition (RTX-resistant NMOSD).
• Reports a median follow-up period of 28.4 months after treatment switch.
• Provides specific counts of patients receiving each alternative therapy (e.g., two on inebilizumab).

Limitations

• Row count and column-level documentation are unknown, limiting suitability assessment.
• Data is from a single-center, retrospective case series of 10 patients, which may limit generalizability.
• Description metadata is limited; actual data quality and structure require manual inspection after download.

Provenance

Source

Meiqun Deng via figshare.

Collection Method

Single-center, retrospective case series.

Time Range

Median follow-up of 28.4 months after treatment switch.

Freshness

Last updated 2026-04-16 05:24:52.

Geography

null